End-points in hepatitis B treatment

References 

1. Liaw YF, Leung N, Guan R, Lau GK, Merican I, McCaughan G, et al., For the Asian-Pacific consensus update working party on chronic hepatitis B. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update. 1 Liver Int 2005;25(3):472–89.
2. Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ, Risk Evaluation of Viral Load Elevation and Associated Liver Disease/Cancer – In HBV (The REVEAL-HBV) Study Group. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006;130(3):678–8.
3. Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, et al., REVEAL-HBV Study Group. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006;295(1):65–73.
4. Lai CL, Chien RN, Leung NWY, Chang TT, Guan R, Tai DI, et al. A one-year trial of lamivudine for chronic hepatitis B. New Engl J Med. 1998;339(2):61–68[see Editorial]
5. Lok AS, Lai CL, Leung N, Yao GB, Cui ZY, Schiff ER, et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology. 2003;125(6):1714–1722
   • Abstract
   • Full Text
   • Full-Text PDF (201 KB)
   • CrossRef
6. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, et al., Cirrhosis Asian Lamivudine Multicentre Study Group. Lamivudine for patients with chronic hepatitis B and advanced liver disease. New Engl J Med 2004;351(15):1521–31.
7. Leung NWY, Lai CL, Chang TT, et al., Asia Hepatitis Lamivudine Study Group. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis e antigen seroconversion rates: results after three years of therapy. Hepatology 2001;33(6):1527–32.
8. Liaw YF, Lee CM, Chien RN, Yeh CT. Switching to adefovir monotherapy after emergence of lamivudine-resistant mutations in patients with liver cirrhosis. J Viral Hepat. 2006;13(4):250–255
   • MEDLINE
   • CrossRef
9. Sherman M, Yurdaydin C, Sollano J, Silva M, Liaw YF, Cianciara J, et al., AI463026 BEHoLD Study Group. Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology 2006;130(7):2039–49.
10. Lai CL, Leung N, Teo EK, Tong M, Wong F, Hann HW, et al., Telbivudine Phase II Investigator Group. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology 2005;129(2):528–36.
11. Marcellin P, Chang TT, Lim SG, Tong MJ, Sievert W, Shiffman ML, et al., Adefovir Dipivoxil 437 Study Group. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. New Engl J Med 2003;348(9):808–16.
12. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, et al., Adefovir Dipivoxil 438 Study Group. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. New Engl J Med 2003;348(9):800–7 [Erratum in: New Engl J Med 2003;348(12):1192].
13. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, et al., Adefovir Dipivoxil 438 Study Group Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5years. Gastroenterology 2006;131(6):1743–51.
14. Chang TT, Gish RG, de Man R, Gadano A, Sollano J, Chao YC, et al., BEHoLD AI463022 Study Group. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. New Engl J Med 2006;354(10):1001–10.
15. Lai CL, Shouval D, Lok AS, Chang TT, Cheinquer H, Goodman Z, et al., BEHoLD AI463027 Study Group. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. New Engl J Med 2006;354(10):1011–20 [Erratum in: New Engl J Med 2006;354(17):1863].
16. Marcellin P, Buti M, Krastev Z, Germanidis G, Kaita KD, Kotzev I, et al. A randomized, double-blind, comparison of tenofovir DF (TDF) for the treatment of HbeAg-negative chronic hepatitis B (CHB): study GS-US-174-0102. Hepatology. 2007;46(4, Suppl. 1):80A
17. Heathcote EJ, Gane E, De Man R, Lee S, Flisiak R, Mann MP, et al. A randomized, double-blind, comparison of tenofovir DF (TDF) versus adefovir dipivoxil (ADV) for the treatment of HbeAg-positive chronic hepatitis B (CHB): study GS-US-174-0103. Hepatology. 2007;46(4, Suppl. 1):861A